MA34838B1 - Composés de pyrazole en tant qu'antagonistes de crth2 - Google Patents

Composés de pyrazole en tant qu'antagonistes de crth2

Info

Publication number
MA34838B1
MA34838B1 MA36130A MA36130A MA34838B1 MA 34838 B1 MA34838 B1 MA 34838B1 MA 36130 A MA36130 A MA 36130A MA 36130 A MA36130 A MA 36130A MA 34838 B1 MA34838 B1 MA 34838B1
Authority
MA
Morocco
Prior art keywords
compounds
pyrazole compounds
crth2 antagonists
pharmaceutical preparations
pyrazole
Prior art date
Application number
MA36130A
Other languages
English (en)
Inventor
Ralf Anderskewitz
Domnic Martyres
Thorsten Oost
Wolfgang Rist
Peter Seither
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43799503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34838(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MA34838B1 publication Critical patent/MA34838B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composés de pyrazole représentés par la formule (1a) ou (1b) et sels pharmaceutiquement acceptables de ces composés, formules dans lesquelles Ra, Rb, Rc, Rd, Y1, y2, y3, y4, y5, Z, R1, R2, n et R3 sont comme définis dans les spécifications et les revendications, leurs utilisations comme médicaments, des préparations pharmaceutiques contenant lesdits composés et des préparations pharmaceutiques des dits composés combinées à un ou plusieurs principes actifs. Ces composés possèdent une activité antagoniste à CTRH2.
MA36130A 2011-01-24 2012-01-20 Composés de pyrazole en tant qu'antagonistes de crth2 MA34838B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11151876 2011-01-24
PCT/EP2012/050830 WO2012101043A1 (fr) 2011-01-24 2012-01-20 Composés de pyrazole en tant qu'antagonistes de crth2

Publications (1)

Publication Number Publication Date
MA34838B1 true MA34838B1 (fr) 2014-01-02

Family

ID=43799503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36130A MA34838B1 (fr) 2011-01-24 2012-01-20 Composés de pyrazole en tant qu'antagonistes de crth2

Country Status (35)

Country Link
US (1) US8759386B2 (fr)
EP (1) EP2668181B1 (fr)
JP (1) JP5695216B2 (fr)
KR (2) KR101923365B1 (fr)
CN (4) CN103339125B (fr)
AP (1) AP3343A (fr)
AR (1) AR084916A1 (fr)
AU (1) AU2012210718B2 (fr)
BR (1) BR112013017570B1 (fr)
CA (1) CA2825458C (fr)
CL (1) CL2013001945A1 (fr)
CO (1) CO6801731A2 (fr)
CY (1) CY1116012T1 (fr)
DK (1) DK2668181T3 (fr)
EA (1) EA022559B1 (fr)
EC (1) ECSP13012832A (fr)
ES (1) ES2529452T3 (fr)
GE (1) GEP20156332B (fr)
HR (1) HRP20150069T1 (fr)
IL (1) IL226920A (fr)
MA (1) MA34838B1 (fr)
MX (1) MX342830B (fr)
MY (1) MY163012A (fr)
PE (1) PE20140860A1 (fr)
PH (2) PH12013501356A1 (fr)
PL (1) PL2668181T3 (fr)
PT (1) PT2668181E (fr)
RS (1) RS53785B1 (fr)
SG (1) SG192096A1 (fr)
SI (1) SI2668181T1 (fr)
TN (1) TN2013000280A1 (fr)
TW (1) TWI527809B (fr)
UA (1) UA109696C2 (fr)
UY (1) UY33873A (fr)
WO (1) WO2012101043A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists
JP5999387B2 (ja) * 2011-03-25 2016-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｒｔｈ２拮抗薬としてのピラゾール化合物
WO2014079805A1 (fr) * 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Composés de pyrazole pour traiter l'alopécie
US20140148492A1 (en) * 2012-11-23 2014-05-29 Boehringer Ingelheim International Gmbh Bicyclosubstituted pyrazole compounds for treating hair loss
EA202092275A1 (ru) * 2018-03-23 2021-02-09 Палатин Текнолоджиз, Инк. Составы пептидов, специфичных к рецептору меланокортина, и способы доставки в желудочно-кишечный тракт
ES2974634T3 (es) 2018-12-21 2024-06-28 Celgene Corp Inhibidores de tienopiridinas de RIPK2
TWI898700B (zh) * 2023-07-03 2025-09-21 南韓商因諾沃治療有限公司 新穎吡唑衍生物及其使用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
CA2390923A1 (fr) * 1999-11-10 2001-05-31 Takeda Chemical Industries, Ltd. Composes heterocycliques n a 5 elements a activite hypoglycemique et hypolipidemique
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
EP1675832B1 (fr) * 2003-10-24 2008-02-20 Glaxo Group Limited Composes heterocyclyles
EP1838690A2 (fr) * 2004-12-21 2007-10-03 Devgen N.V. Composés avec une activité pour les canaux ioniques kv4
JP4950542B2 (ja) * 2006-04-07 2012-06-13 岩手東芝エレクトロニクス株式会社 固体撮像装置およびその製造方法
EP2040700B1 (fr) 2006-06-06 2010-11-24 Glaxo Group Limited Dérivés de n- (phénylméthyl) -2- (1h-pyraz0l-4-yl) acétamide utilisés comme antagonistes fp2x7 pour le traitement de la douleur, de l'inflammation et de la neurodégénérescence
JP4469924B2 (ja) * 2006-11-27 2010-06-02 ファイザー・プロダクツ・インク ピラゾール類似体
EP2205569B1 (fr) 2007-09-25 2012-02-29 Actimis Pharmaceuticals, Inc., Alkylthiopyrimidines en tant qu'antagonistes de crth2
KR20100061746A (ko) * 2007-09-25 2010-06-08 액티미스 파마수티컬스 인코포레이티드 Ｃｒｔｈ２ 길항제로서의 ２－ｓ－벤질 치환된 피리미딘
JP2011088826A (ja) * 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
MX2010014172A (es) * 2008-07-03 2011-02-22 Amira Pharmaceuticals Inc Antagonistas de receptores de prostaglandina d2.
GB2463788B (en) * 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
US8383654B2 (en) 2008-11-17 2013-02-26 Panmira Pharmaceuticals, Llc Heterocyclic antagonists of prostaglandin D2 receptors
JP2012517405A (ja) * 2009-02-09 2012-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器及び胃腸の疾患の治療のための新規医薬組成物
ES2545865T3 (es) * 2010-01-27 2015-09-16 Boehringer Ingelheim International Gmbh Compuestos de pirazol como antagonistas de CRTH2
JP2013535457A (ja) * 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
US8759386B2 (en) * 2011-01-24 2014-06-24 Boehringer Ingelheim International Gmbh Pyrazole compounds as CRTH2 antagonists

Also Published As

Publication number Publication date
CL2013001945A1 (es) 2013-10-25
PH12018501531A1 (en) 2019-04-08
KR102251939B1 (ko) 2021-05-14
US20130023576A1 (en) 2013-01-24
UY33873A (es) 2012-07-31
ES2529452T3 (es) 2015-02-20
IL226920A (en) 2016-11-30
TN2013000280A1 (en) 2014-11-10
CY1116012T1 (el) 2017-01-25
CA2825458C (fr) 2021-01-26
CN103339125A (zh) 2013-10-02
AP3343A (en) 2015-07-31
JP5695216B2 (ja) 2015-04-01
KR20140005931A (ko) 2014-01-15
JP2014502986A (ja) 2014-02-06
TW201245184A (en) 2012-11-16
CN107011332B (zh) 2020-03-13
HK1210467A1 (en) 2016-04-22
HK1186183A1 (en) 2014-03-07
PE20140860A1 (es) 2014-07-20
PH12013501356A1 (en) 2013-09-02
EP2668181A1 (fr) 2013-12-04
CN104628705B (zh) 2017-04-12
KR101923365B1 (ko) 2018-11-30
CA2825458A1 (fr) 2012-08-02
GEP20156332B (en) 2015-07-27
EP2668181B1 (fr) 2014-11-05
WO2012101043A1 (fr) 2012-08-02
HRP20150069T1 (hr) 2015-02-27
AR084916A1 (es) 2013-07-10
KR20180129962A (ko) 2018-12-05
BR112013017570A2 (pt) 2016-10-18
MX342830B (es) 2016-10-14
CN104961732A (zh) 2015-10-07
AU2012210718A1 (en) 2013-07-04
SI2668181T1 (sl) 2015-02-27
PT2668181E (pt) 2015-02-05
AP2013006942A0 (en) 2013-06-30
SG192096A1 (en) 2013-08-30
MX2013008082A (es) 2013-09-13
HK1215247A1 (zh) 2016-08-19
MY163012A (en) 2017-07-31
AU2012210718B2 (en) 2016-06-02
EA022559B1 (ru) 2016-01-29
CN104961732B (zh) 2017-07-11
TWI527809B (zh) 2016-04-01
DK2668181T3 (da) 2015-01-19
CN103339125B (zh) 2015-07-15
CN107011332A (zh) 2017-08-04
ECSP13012832A (es) 2013-09-30
CO6801731A2 (es) 2013-11-29
EA201300857A1 (ru) 2013-12-30
US8759386B2 (en) 2014-06-24
NZ611695A (en) 2015-04-24
UA109696C2 (xx) 2015-09-25
BR112013017570B1 (pt) 2022-01-11
RS53785B1 (sr) 2015-06-30
CN104628705A (zh) 2015-05-20
PL2668181T3 (pl) 2015-04-30

Similar Documents

Publication Publication Date Title
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA37762A1 (fr) Composés n-aryltriazole utilisés comme antagonistes de lpar
AR068768A1 (es) Derivados de tetrahidroquinolina para tratar trastornos por estres post - traumatico
MA34727B1 (fr) Imidazolylimidazoles condensés utilisés comme composés antiviraux
MA33384B1 (fr) Sulfonamides hétérocycliques, leurs utilisations et compositions pharmaceutiques les contenant
PH12018501531A1 (en) Pyrazole compounds as crth2 antagonists
BR112015021791A2 (pt) lipídios e composições de lipídios para a liberação de agentes ativos
UA112317C2 (uk) Похідні 2-(1,2,3-триазол-2-іл)бензаміду та 3-(1,2,3-триазол-2-іл)піколінаміду як антагоністи рецептора орексину
NO20082269L (no) Nye piperaziner som antimalariamidler
MY160036A (en) Pyrazole compounds as crth2 antagonists
MA35941B1 (fr) Préparation pharmaceutique contenant un dérivé de dihydrochinazoline à action antivirale
MA46229B1 (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
MA38854A1 (fr) Dérivés amides utilisés en tant qu'antagonistes des récepteurs de l'acide lysophosphatidique
MA37765A1 (fr) Composés de pyrazole substitués utilisés comme antagonistes de lpar
CY1111102T1 (el) 2-(4-κυανοφαινυλ)-6-υδροξυλαμινοπυριμιδινες που αναστελλουν τον hiv
MA38679A1 (fr) Modulateurs du récepteur de cxcr7
MA33563B1 (fr) 5-(3,4-dichloro-phényl)-n-(2-hydroxy-cyclohexyl)-6-(2,2,2-trifluoro-éthoxy)-nicotinamide et ses sels utilisés comme agents augmentant le cholestérol hdl
MA44965B1 (fr) Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3
JO3029B1 (ar) مشتقات مبتكرة مضادة للفطريات ل 5 ، 6 - ثاني هيدرو - 4- [(ثاني فلورو اثيل) فينيل] -4 H - بيرولو [2،1 -a ] [1،4] بينزوديازيبين و 4- ( ثاني فلورو اثيل ) فينيل - 6 H - بيرولو [2،1 -a ] [1،4] بينزوديازيبين
MA33979B1 (fr) Piperazines en tant qu'agents antipaludiques
BR112013028197A2 (pt) compostos de benzofurano-piperidina
EP2842938A4 (fr) Nouveaux dérivés de bêta-alanine, leurs sels pharmaceutiquement acceptables et composition pharmaceutique les comprenant en tant qu'ingrédient actif
MA33055B1 (fr) Nouvelle combinaison de principes actifs contenant un anti-inflammatoire non steroidien et un derive de colchicoside
MA37741B1 (fr) Dérivés de benzimidazole-proline
MA39149B1 (fr) Analogues de cortistatine et synthèses et utilisations associées